FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171880801> ?p ?o ?g. }

• W2171880801 endingPage "602" @default.
• W2171880801 startingPage "592" @default.
• W2171880801 abstract "BackgroundAccumulating evidence suggests an association between autism spectrum disorders (ASD) and inflammation in brain regions related to cognitive function. The natural flavonoid luteolin has antioxidant, anti-inflammatory, mast cell–blocking, and neuroprotective effects. It was shown to improve cognitive performance in a mouse model of ASD, but its effect in humans has not been adequately studied.ObjectivesThe goal of this study was to assess the effectiveness and tolerability in white children with ASD of a dietary supplement containing 2 flavonoids (>95% pure), luteolin (100 mg/capsule, from chamomile) and quercetin (70 mg/capsule), and the quercetin glycoside rutin (30 mg/capsule) from the Sophora japonica leaf, formulated in olive kernel oil to increase oral absorption.MethodsFifty children (4–10 years old; 42 boys and 8 girls) with ASD were enrolled in a 26-week, prospective, open-label trial at the 2nd University Department of Psychiatry at “Attikon” General Hospital, Athens, Greece. Children were referred for the study by their respective physicians or came from the practice of the senior author. ASD diagnosis by clinical assessment was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, symptom list and corroborated by using the Autism Diagnostic Observation Schedule. The dose of the study formulation used was 1 capsule per 10 kg weight per day with food. The primary outcome measures were the age-equivalent scores in the Vineland Adaptive Behavior Scales domains. Secondary outcomes included the Aberrant Behavior Checklist, the Autism Treatment Evaluation Checklist, and the Clinical Global Impression–Improvement score. Data were measured at baseline, week 18, and week 26. Parents were interviewed for any possible improvements they noticed and instructed to report any unusual adverse events.ResultsA total of 40 children completed the protocol. There was a significant improvement in adaptive functioning as measured by using the VABS age-equivalent scores (8.43 months in the communication domain, 7.17 months in daily living skills, and 8 months in the social domain; P < 0.005), as well as in overall behavior as indicated by the reduction (26.6%–34.8%) in Aberrant Behavior Checklist subscale scores. Age, sex, and history of allergies had no effect on the results, whereas the initial level of functioning or difficulty did predict the final outcome in most of the measures used. There was a transient (1–8 weeks) increased irritability in 27 of the 50 participants.ConclusionsThese results are encouraging in that the combination of the flavonoids luteolin and quercetin seemed to be effective in reducing ASD symptoms, with no major adverse effects. ClinicalTrials.gov identifier: NCT01847521." @default.
• W2171880801 created "2016-06-24" @default.
• W2171880801 creator A5005117637 @default.
• W2171880801 creator A5006346169 @default.
• W2171880801 creator A5010488610 @default.
• W2171880801 creator A5054805471 @default.
• W2171880801 date "2013-05-01" @default.
• W2171880801 modified "2023-10-06" @default.
• W2171880801 title "An Open-Label Pilot Study of a Formulation Containing the Anti-Inflammatory Flavonoid Luteolin and Its Effects on Behavior in Children With Autism Spectrum Disorders" @default.
• W2171880801 cites W1480803791 @default.
• W2171880801 cites W1490834367 @default.
• W2171880801 cites W1505731461 @default.
• W2171880801 cites W1600943356 @default.
• W2171880801 cites W1605138144 @default.
• W2171880801 cites W1960998321 @default.
• W2171880801 cites W1968430210 @default.
• W2171880801 cites W1979919872 @default.
• W2171880801 cites W1981513791 @default.
• W2171880801 cites W1984486655 @default.
• W2171880801 cites W1988470413 @default.
• W2171880801 cites W1992779539 @default.
• W2171880801 cites W2000554656 @default.
• W2171880801 cites W2018303280 @default.
• W2171880801 cites W2023939312 @default.
• W2171880801 cites W2026674010 @default.
• W2171880801 cites W2030242565 @default.
• W2171880801 cites W2032095437 @default.
• W2171880801 cites W2032504520 @default.
• W2171880801 cites W2057244692 @default.
• W2171880801 cites W2062746439 @default.
• W2171880801 cites W2081935323 @default.
• W2171880801 cites W2083366087 @default.
• W2171880801 cites W2098951793 @default.
• W2171880801 cites W2102160051 @default.
• W2171880801 cites W2104671744 @default.
• W2171880801 cites W2111587484 @default.
• W2171880801 cites W2112359022 @default.
• W2171880801 cites W2116795013 @default.
• W2171880801 cites W2118940666 @default.
• W2171880801 cites W2121150539 @default.
• W2171880801 cites W2122275317 @default.
• W2171880801 cites W2124736741 @default.
• W2171880801 cites W2137742585 @default.
• W2171880801 cites W2142376155 @default.
• W2171880801 cites W2144312770 @default.
• W2171880801 cites W2144446993 @default.
• W2171880801 cites W2145914632 @default.
• W2171880801 cites W2149557299 @default.
• W2171880801 cites W2155904360 @default.
• W2171880801 cites W2157920869 @default.
• W2171880801 cites W2167538265 @default.
• W2171880801 cites W2471099003 @default.
• W2171880801 doi "https://doi.org/10.1016/j.clinthera.2013.04.006" @default.
• W2171880801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23688534" @default.
• W2171880801 hasPublicationYear "2013" @default.
• W2171880801 type Work @default.
• W2171880801 sameAs 2171880801 @default.
• W2171880801 citedByCount "159" @default.
• W2171880801 countsByYear W21718808012013 @default.
• W2171880801 countsByYear W21718808012014 @default.
• W2171880801 countsByYear W21718808012015 @default.
• W2171880801 countsByYear W21718808012016 @default.
• W2171880801 countsByYear W21718808012017 @default.
• W2171880801 countsByYear W21718808012018 @default.
• W2171880801 countsByYear W21718808012019 @default.
• W2171880801 countsByYear W21718808012020 @default.
• W2171880801 countsByYear W21718808012021 @default.
• W2171880801 countsByYear W21718808012022 @default.
• W2171880801 countsByYear W21718808012023 @default.
• W2171880801 crossrefType "journal-article" @default.
• W2171880801 hasAuthorship W2171880801A5005117637 @default.
• W2171880801 hasAuthorship W2171880801A5006346169 @default.
• W2171880801 hasAuthorship W2171880801A5010488610 @default.
• W2171880801 hasAuthorship W2171880801A5054805471 @default.
• W2171880801 hasConcept C118552586 @default.
• W2171880801 hasConcept C185592680 @default.
• W2171880801 hasConcept C187212893 @default.
• W2171880801 hasConcept C205778803 @default.
• W2171880801 hasConcept C2776080593 @default.
• W2171880801 hasConcept C2778004101 @default.
• W2171880801 hasConcept C2778538070 @default.
• W2171880801 hasConcept C2779054382 @default.
• W2171880801 hasConcept C2780055620 @default.
• W2171880801 hasConcept C55493867 @default.
• W2171880801 hasConcept C71924100 @default.
• W2171880801 hasConceptScore W2171880801C118552586 @default.
• W2171880801 hasConceptScore W2171880801C185592680 @default.
• W2171880801 hasConceptScore W2171880801C187212893 @default.
• W2171880801 hasConceptScore W2171880801C205778803 @default.
• W2171880801 hasConceptScore W2171880801C2776080593 @default.
• W2171880801 hasConceptScore W2171880801C2778004101 @default.
• W2171880801 hasConceptScore W2171880801C2778538070 @default.
• W2171880801 hasConceptScore W2171880801C2779054382 @default.
• W2171880801 hasConceptScore W2171880801C2780055620 @default.
• W2171880801 hasConceptScore W2171880801C55493867 @default.
• W2171880801 hasConceptScore W2171880801C71924100 @default.
• W2171880801 hasIssue "5" @default.
• W2171880801 hasLocation W21718808011 @default.

• next